Development of topical microbicides for prevention of human immunodeficiency virus and herpes simplex virus

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Topical microbicides, designed for vaginal or rectal administration, are needed to prevent human immunodeficiency virus (HIV) and other sexually transmitted infections (STI). Presently marketed topical microbicides are cytotoxic and damage the vaginal epithelium with frequent use. Rational development of new candidate compounds should build on knowledge of the pathways of microbial invasion. The establishment of assays and models that predict efficacy and safety is critical. Comprehensive pre-clinical evaluation of promising microbicides should include rigorous assessment of the effects of repeated application of topical agents on mucosal inflammatory cells, cytokines, and the genital tract virus population. These studies will lay the groundwork for future clinical trials.

Original languageEnglish (US)
Pages (from-to)279-284
Number of pages6
JournalAmerican Journal of Reproductive Immunology
Volume49
Issue number5
DOIs
StatePublished - May 1 2003
Externally publishedYes

Fingerprint

Local Anti-Infective Agents
Simplexvirus
Intravaginal Administration
HIV
Rectal Administration
Sexually Transmitted Diseases
Anti-Infective Agents
Epithelium
Clinical Trials
Cytokines
Viruses
Safety
Population

Keywords

  • Genital tract
  • Inflammation
  • Microbicide
  • Sexually transmitted infections

ASJC Scopus subject areas

  • Immunology
  • Obstetrics and Gynecology

Cite this

@article{d10eb17deecd4d6d85ea5beb70dec380,
title = "Development of topical microbicides for prevention of human immunodeficiency virus and herpes simplex virus",
abstract = "Topical microbicides, designed for vaginal or rectal administration, are needed to prevent human immunodeficiency virus (HIV) and other sexually transmitted infections (STI). Presently marketed topical microbicides are cytotoxic and damage the vaginal epithelium with frequent use. Rational development of new candidate compounds should build on knowledge of the pathways of microbial invasion. The establishment of assays and models that predict efficacy and safety is critical. Comprehensive pre-clinical evaluation of promising microbicides should include rigorous assessment of the effects of repeated application of topical agents on mucosal inflammatory cells, cytokines, and the genital tract virus population. These studies will lay the groundwork for future clinical trials.",
keywords = "Genital tract, Inflammation, Microbicide, Sexually transmitted infections",
author = "Keller, {Marla J.} and Klotman, {M. E.} and Betsy Herold",
year = "2003",
month = "5",
day = "1",
doi = "10.1034/j.1600-0897.2003.00044.x",
language = "English (US)",
volume = "49",
pages = "279--284",
journal = "American Journal of Reproductive Immunology and Microbiology",
issn = "1046-7408",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Development of topical microbicides for prevention of human immunodeficiency virus and herpes simplex virus

AU - Keller, Marla J.

AU - Klotman, M. E.

AU - Herold, Betsy

PY - 2003/5/1

Y1 - 2003/5/1

N2 - Topical microbicides, designed for vaginal or rectal administration, are needed to prevent human immunodeficiency virus (HIV) and other sexually transmitted infections (STI). Presently marketed topical microbicides are cytotoxic and damage the vaginal epithelium with frequent use. Rational development of new candidate compounds should build on knowledge of the pathways of microbial invasion. The establishment of assays and models that predict efficacy and safety is critical. Comprehensive pre-clinical evaluation of promising microbicides should include rigorous assessment of the effects of repeated application of topical agents on mucosal inflammatory cells, cytokines, and the genital tract virus population. These studies will lay the groundwork for future clinical trials.

AB - Topical microbicides, designed for vaginal or rectal administration, are needed to prevent human immunodeficiency virus (HIV) and other sexually transmitted infections (STI). Presently marketed topical microbicides are cytotoxic and damage the vaginal epithelium with frequent use. Rational development of new candidate compounds should build on knowledge of the pathways of microbial invasion. The establishment of assays and models that predict efficacy and safety is critical. Comprehensive pre-clinical evaluation of promising microbicides should include rigorous assessment of the effects of repeated application of topical agents on mucosal inflammatory cells, cytokines, and the genital tract virus population. These studies will lay the groundwork for future clinical trials.

KW - Genital tract

KW - Inflammation

KW - Microbicide

KW - Sexually transmitted infections

UR - http://www.scopus.com/inward/record.url?scp=0037716610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037716610&partnerID=8YFLogxK

U2 - 10.1034/j.1600-0897.2003.00044.x

DO - 10.1034/j.1600-0897.2003.00044.x

M3 - Article

VL - 49

SP - 279

EP - 284

JO - American Journal of Reproductive Immunology and Microbiology

JF - American Journal of Reproductive Immunology and Microbiology

SN - 1046-7408

IS - 5

ER -